Newly developed retatrutide, a dual -action drug targeting equally GLP-1 and GIP receptors, is sparking considerable excitement within the medical community. Preliminary clinical trials have demonstrated substantial reductions in body mass and gains in physiological markers for people with overweight. Experts believe this ground-breaking approa… Read More